Compare MobilEye Global Inc (MBLY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Regeneron Pharmaceuticals Inc — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $6.00B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.7× MobilEye Global Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MBLY | REGN | |
|---|---|---|
Market Cap | $6.00B | $76.14B |
Volume | 7,007,849 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $852.03 |
52-Week Low | $6.56 | $557.73 |
Typical Hold Time | 15 Days | 107 Days |
Enterprise Value | $4.56B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $7.15, down 4.28% today, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus remains positive with a $10.83 price target.
The stock presents a high-risk opportunity with strong analyst support but persistent profitability challenges. Upside potential exists from autonomous driving adoption and new program ramps, offset by execution risks and negative cash flow projections for 2026. Current valuation below book value offers margin of safety for long-term investors willing to withstand volatility.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
